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Abstract: The human whipworm, Trichuris trichiura, is estimated to infect 289.6 million people
globally. Control of human trichuriasis is a particular challenge, as most anthelmintics have a limited
single-dose efficacy, with the striking exception of the narrow-spectrum anthelmintic, oxantel. We
recently identified a novel ACR-16-like subunit from the pig whipworm, T. suis which gave rise to
a functional acetylcholine receptor (nAChR) preferentially activated by oxantel. However, there is
no ion channel described in the mouse model parasite T. muris so far. Here, we have identified the
ACR-16-like and ACR-19 subunits from T. muris, and performed the functional characterization of the
receptors in Xenopus laevis oocytes using two-electrode voltage-clamp electrophysiology. We found
that the ACR-16-like subunit from T. muris formed a homomeric receptor gated by acetylcholine
whereas the ACR-19 failed to create a functional channel. The subsequent pharmacological analysis
of the Tmu-ACR-16-like receptor revealed that acetylcholine and oxantel were equally potent. The
Tmu-ACR-16-like was more responsive to the toxic agonist epibatidine, but insensitive to pyrantel, in
contrast to the Tsu-ACR-16-like receptor. These findings confirm that the ACR-16-like nAChR from
Trichuris spp. is a preferential drug target for oxantel, and highlights the pharmacological difference
between Trichuris species.
Keywords: Trichuris; antiparasitic drugs; oxantel; nAChR; helminths; electrophysiology; Xenopus
oocytes
1. Introduction
The human whipworm, Trichuris trichiura, is a Clade I parasitic nematode [1] and
one of the Soil-Transmitted Helminths (STHs) which include the roundworm Ascaris
lumbricoides and the hookworms Ancylostoma duodenale and Necator americanus. Trichuris
trichiura is estimated to infect 289.6 million people globally, primarily living in low- and
middle-income countries [2]. Infection with T. trichiura is rarely fatal, but affects the health
and the nutritional status of the host [3,4]. High intensity infections are responsible for
dysentery syndrome, anemia, finger clubbing and rectal prolapse [5]. Control of trichuriasis
(and STHs in general) relies on hygiene education, access to appropriate sanitation and
periodic mass drug administration of the anthelmintic drugs, albendazole and mebendazole
which belong to the benzimidazoles anthelmintic drug class [6]. However, trichuriasis
has proven notoriously difficult to control using a single-oral-dose treatment regime with
these drugs [7–12] and there are only a few anthelmintic drugs effective against Trichuris
infections. One of these is oxantel, which is a m-oxyphenol of pyrantel which belongs to the
tetrahydropyrimidine chemical class. Oxantel was developed in 1972 [13] and marketed
in 1974 as a veterinary, narrow-spectrum anthelmintic, specifically for the treatment of
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Trichuris [14]. Clinical trials have shown oxantel to be more efficient than albendazole and
mebendazole for the control of trichuriasis [15–18].
Trichuris muris is a natural whipworm of rodents that bears some common features
to T. trichiura and serves as a laboratory system to study human whipworm infection.
T. muris is widely used as a model for anthelminthic screenings in vitro as well as for the
clinical assessment of anthelmintic efficacy in vivo [19–22]. T. muris has several advantages
as the adult worms are more accessible than T. trichiura obtained from humans, it has a
shorter prepatent time than the pig whipworm T. suis, also used as a model for T. trichiura
(i.e., 32 days versus 41–49 days) [23–25], hence obtaining Trichuris from mice is less labor-
and cost intensive than from pigs. It is, therefore, important to identify and characterize
anthelmintic drug targets from T. muris to further understand the mode of action of current
compounds such as oxantel, and to evaluate novel anthelmintic compounds alone or
in combinations.
Cholinergic anthelmintics, such as oxantel [26], exert their anthelmintic effect by par-
alyzing the worms which are subsequently expelled from the host or killed [27]. This
effect is mediated by nicotinic acetylcholine receptors (nAChRs) which are pentameric
proteins that are either homomeric- or heteromeric ligand-gated ion channels expressed
in neuronal-, non-neuronal and muscle cell membranes [28,29]. Previously, no ion chan-
nel from Clade I parasitic nematodes had been characterized. Recently, we identified a
preferential drug target for oxantel from the pig whipworm T. suis, and achieved its func-
tional characterization in Xenopus laevis oocytes and the free-living nematode Caenorhabditis
elegans. This drug target is a homomeric acetylcholine receptor (AChR), constituted of
five ACR-16-like subunits that are specific to Clade I nematodes [30]. Due to the high
oxantel sensitivity of this receptor, and in reference to the previously reported L-AChR,
N-AChR, B-AChR and M-AChR (respectively for Levamisole-sensitive, Nicotine-sensitive,
Bephenium-sensitive and Morantel-sensitive) [31,32], we referred to this Tsu-ACR-16-like
receptor as an O-AChR subtype.
Caenorhabditis elegans possesses one of the most extensive, and diverse nAChR gene
family [33], with 29 nAChR subunits divided into five groups based on sequence homology
and named after the first of their number to be discovered [34]. One of these groups, the
ACR-16 group, contains 11 genes [34], which is in sharp contrast to the low number of
nAChR subunits found within the ACR-16 group of Clade I parasitic nematodes. In our
previous database search for a potential oxantel target within Trichuris spp., we identified
only two nAChR subunits from the ACR-16 group of Trichuris spp. [30]. This was in
accordance with Williamson et al. [35], who reported only two members from the ACR-16
group in the genomic data from the closely related Clade I parasitic nematode Trichinella
spiralis. One was the ACR-16-like subunit, which constituted the O-AChR from T. suis,
while the other was a clear orthologue of the ACR-19 subunit from C. elegans (Cel-ACR-19).
In contrast to T. suis, to date there are currently no ion channels of T. muris characterized
and the respective roles of the ACR-16 group subunits have not yet been investigated in
this important model species. Here, we aimed to characterize the ACR-16-like and ACR-19
subunits from T. muris at the functional level. We achieved the functional reconstitution of a
T. muris oxantel-sensitive AChR in the Xenopus oocyte expression system and compared the
pharmacological properties of the O-AChRs from T. muris versus T. suis. Our results show
that the O-AChR subtype from T. muris is highly sensitive to oxantel, thus additionally
explain the high efficacy and specificity of oxantel on whipworm species. Finally, our
results highlight the pharmacological differences of the O-AChRs between Trichuris species
and emphasize the lack of knowledge around parasitic receptor compositions.
2. Results
2.1. Identification of ACR-16-Like and ACR-19 Sequences from Trichuris muris
Trichuris muris is, as with T. suis, used as a model for T. trichiura. Oxantel was pre-
viously shown to act on the nAChR made of ACR-16-like subunits from T. suis [30]. To
investigate the ACR-16-like nAChR from T. muris, we identified and cloned the full-length
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coding sequence of the T. muris acr-16-like subunit cDNA (Tmu-acr-16-like). The cloned
T. muris acr-16-like sequence differed from the putative full-length Tmu-acr-16-like cDNA
sequence available in WormBase (accession number WBGene00290200) by two synony-
mous nucleotide substitutions (CCG → CCA at codon 327 and AGT → AGC at codon
427), and was therefore deposited in GenBank under the accession number MZ322663. To
explore all the members of the ACR-16 group of Trichuris spp, we performed searches in
genomic databanks that led to the identification of the C. elegans acr-19 gene orthologue
in T. muris [30]. Consequently, the full-length Tmu-acr-19 cDNA sequence was amplified
by PCR and subsequently cloned and sequenced. Our clone was identical to the puta-
tive full-length Tmu-acr-19 cDNA sequence available in WormBase (accession number
WBGene00291941). An amino-acid alignment of the Tmu-ACR-16-like and Tmu-ACR-19
sequences with their related counterparts from T. suis and T. trichiura is shown in Figure 1.
The nematode ACR-16 nAChR subunit has been described as a homolog of the mammalian
α7 nAChR subunit, for comparison, the amino-acid sequence of the human α7 subunit is
therefore included in the alignment [36–38]. The Tmu-ACR-16-like subunit is 464 amino
acids long and shares 90 and 91% identities with the ACR-16-like subunits from T. suis
and T. trichiura, respectively. For comparison, the ACR-16-like subunits from T. suis and
T. trichiura share 93% identities. The Tmu-ACR-16-like subunit shares 42% identities with
the human α7 subunit. The Tmu-ACR-19 subunit is 497 amino acids long, and shares 78
and 88% identities with the ACR-19 subunits from T. suis and T. trichiura, respectively.
The ACR-16-like- and the ACR-19 subunit sequences from T. muris and T. suis all share
typical features of nAChR subunits including a predicted signal peptide, four transmem-
brane areas (TM1-TM4), a Cys-loop motif and the YxCC motif that characterizes an α-type
nAChR receptor subunit. The extracellular domain (ECDs) ligand binding loops A-E of the
ACR-16-like subunits from Trichuris spp. and the ACR-16 subunits from Clade III (Ascaris
suum, Parascaris equorum) and Clade V (C. elegans, A. ceylanicum, A. caninum, N. americanus,
Haemonchus contortus) nematodes [1] are shown in Figure S1. The ECDs are based on a
homology model of the ECDs of the ACR-16 subunit from A. ceylanicum, N. americanus,
C. elegans, and T. muris performed by Kaji et al. [38]. The ligand binding loops of the
ACR-16-like subunit from Trichuris spp. are in general different from Clade III and V nema-
todes. However, among the Trichuris spp. the ligand binding loops of the Tmu-ACR-16-like
subunit is the most divergent. In total, the ACR-16-like subunit of T. muris has seven
residues in loop E, F, and C, respectively, which differ from the corresponding residues in
the ACR-16-like subunit of T. suis and T. trichiura (i.e., loop E: Tyr138 and Gly140 instead of
His and Ser, loop F: Ser189 instead of Asn, loop C: Lys210, Lys214, Asn217, and Asp221
instead of Ile, Gln, Thr, and Asn, respectively, Figure S1). In contrast, the binding loops
of T. suis and T. trichiura are highly similar, with only one residue in loop E that differs
(Met144 in T. suis instead of Val in T. muris and T. trichiura).
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Figure 1. Amino-acid alignment of ACR-16-like and ACR-19 subunits from T. muris, T. suis and T. trichiura and the human 
α7 subunit Predicted signal peptide sequences are shaded in dark green, the Cys-loop, the transmembrane regions (TM1-
TM4) and the YxCC motif is shown below the sequences. Conserved amino acids between ACR-16-like and ACR-19 sub-
unit sequences are highlighted in black, conserved amino acids for ACR-16-like and ACR-19 are highlighted with red and 
green, respectively, nematode specific amino acids are highlighted in grey. 
2.2. The T. muris ACR-16-Like Subunit Forms a Functional Acetylcholine Receptor in Xenopus 
Laevis Oocytes 
To investigate potential functional nAChRs made of T. muris ACR-16-like and ACR-
19 subunits, we microinjected their corresponding cRNAs in X. laevis oocytes and re-
sponses to agonists were subsequently monitored using two-electrode voltage-clamp 
(TEVC) electrophysiology. The cRNA of the X. laevis chaperone protein Resistance to In-
hibitors of Cholinesterase ric-3 was also added to the respective subunit cRNAs as it is 
required to promote the expression of nAChRs [30,37–41]. We found that injections of the 
Tmu-acr-16-like cRNA led to the robust expression of a functional homomeric receptor, 
which elicited a response in the μA range when exposed to 100 μM acetylcholine (ACh) 
(Figures 2 and 3a). In contrast to injection with the Tmu-acr-16-like cRNA, the injections of 
Tmu-acr-19 cRNAs never led to recordings of ACh-elicited currents (n = 14), indicating 
that this subunit did not form a functional homomeric ACh-sensitive channel. To phar-
macologically characterize the Tmu-ACR-16-like receptor, we assayed four cholinergic an-
thelmintics (i.e., oxantel, pyrantel, morantel and levamisole) and five nicotinic agonists 
(i.e., epibatidine, anabasine, nicotine, dimethyl phenyl piperazine (DMPP) and cytisine) 
all at a concentration of 100 μM. For each oocyte, all responses induced by each compound, 
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2.2. he . uris -16-Like Subunit For s a Functional cetylcholine eceptor in enopus
laevis Oocytes
investigate potential functional nAChRs made of T. muris ACR-16-like and ACR-19
subunits, we microinjected their cor esponding cRNAs in X. laevis oocytes and responses
to agonists were subsequ ntly monitored using two-electrode voltage-clamp (TEVC) elec-
trophysiology. The cRNA of the X. laevis chaperone prot in Resistance to Inhibitors of
Cholinesterase ric-3 was also added to the respective subunit cRNAs as it is required to
promote the expression of nAChRs [30,37–41]. We found that injections of the Tmu-acr-16-
like cRNA led to the robust expression of a functional homomeric receptor, which elicited a
response in the µA range when exposed to 100 µM acetylcholine (ACh) (Figures 2 and 3a).
In contrast to injection with the Tmu-acr-16-like cRNA, the injections of Tmu-acr-19 cRNAs
never led to recordings of ACh-elicited currents (n = 14), indicating that this subunit did not
form a functional homomeric ACh-sensitive channel. To pharmacologically characterize
the Tmu-ACR-16-like receptor, we assayed four cholinergic anthelmintics (i.e., oxantel,
pyrantel, morantel and levamisole) and five nicotinic agonists (i.e., epibatidine, anabasine,
nicotine, dimethyl phenyl piperazine (DMPP) and cytisine) all at a concentration of 100 µM.
For each oocyte, all responses induced by each compound, were normalized to the response
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of 100 µM ACh. The relative current responses of these compounds are given in Figure 2 as
a scatter dot plot with normalized means ± SEM, along with representative traces and the
number of oocytes (n) used for each agonist. When oxantel and epibatidine were applied
onto the oocytes, we could record large µA currents corresponding to 51.5 ± 3.6% and
48.3 ± 5.0% of the 100 µM ACh response, respectively. Interestingly, oxantel and epiba-
tidine induced significantly higher current responses on the Tmu-ACR-16-like receptor
than any of the other agonists tested (p < 0.02), including pyrantel (4.6 ± 0.8%), which
chemical structure is very similar to oxantel. Levamisole, cytisine, and morantel did not
elicit any current. The rank order potency series for the compounds tested was oxantel =
epibatidine > pyrantel ~ anabasine ~ DMPP ~ nicotine > morantel = cytosine = levamisole
thus showing that this receptor is different from nicotine, pyrantel, and levamisole receptor
subtypes described in other nematode species.
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above the traces, the perfusion time of each compound was 10 s as indicated with short bars above the traces.




Figure 3. Concentration-response relationships. (a) Representative current traces of individual 
Xenopus oocytes expressing the Tmu-ACR-16-like receptor challenged with increasing concentra-
tions of ACh (blue), oxantel (red) and epibatidine (green). Compounds were applied for 10 s (short 
bars); (b) Concentration-response curves of ACh, oxantel and epibatidine on the Tmu-ACR-16-like 
receptor; (c) Concentration-response curves for epibatidine on the ACR-16-like receptor from T. mu-
ris (also shown in a) and T. suis; (d) Concentration-response curves for ACh on eggs microinjected 
either with Tmu-acr-16-like cRNA (also shown in a) or with Tmu-acr-16-like and Tmu-acr-19 cRNAs. 
Figure 3. Concentration-response relationships. (a) Representative current traces of individual
Xenopus oocytes expressing the Tmu-ACR-16-like receptor challenged with increasing concentrations
of ACh (blue), oxantel (red) and epibatidine (green). Compounds were applied for 10 s (short bars);
(b) Concentration-response curves of ACh, oxantel and epibatidine on the Tmu-ACR-16-like receptor;
(c) Concentration-response curves f r epib tidine on th ACR-16-like receptor from T. muris (also
shown in a) and T. suis; (d) Concentration-response curves for ACh on eggs microinjected either with
Tmu-acr-16-like cRNA (also shown in a) or with Tmu-acr-16-like and Tmu-acr-19 cRNAs. All current
responses are normalized to current responses induced by 300 µM ACh and given as mean ± SEM.
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2.3. Characterization of ACh, Oxantel, and Epibatidine Effects on T. muris and T. suis
ACR-16-Like AChRs
Oxantel has previously been shown to act as a full agonist on the ACR-16-like receptor
from T. suis, whereas epibatidine only induced a minor response. Full concentration-
response experiments were carried out to explore the ACR-16-like channels sensitivities
to ACh, oxantel, and epibatidine from T. muris versus T. suis. Concentration-response
relationships for ACh, oxantel and epibatidine on the Tmu-ACR-16-like receptor are shown
in Figure 3a,b. The ACh concentration-response curve was characterized by an EC50 value
of 31.1 ± 0.3 µM (mean ± SEM, n = 16). The highest current response was measured with
300 µM ACh, hence, all other measurements were normalized to the current response at
300 µM ACh. We found that the oxantel EC50 value of the Tmu-ACR-16-like receptor was
32.7 ± 0.3 µM (n = 18) suggesting that oxantel and ACh were equally potent. Surprisingly,
epibatidine was found to be the most potent compound on the Tmu-ACR-16-like receptor
with an EC50 of 1.7 ± 0.4 µM (n = 11). Acetylcholine had the highest efficacy with an
Imax (mean ± SEM) of 94.7 ± 0.7% followed by 37.9 ± 0.3% for oxantel and 25.7 ± 0.5%
for epibatidine (p < 0.0001). To compare the pharmacological properties of the ACR-16-
like receptor from T. muris to that of T. suis, we further performed the concentration-
response relationship for epibatidine on the Tsu-ACR-16-like receptor. Figure 3c shows the
comparison of the concentration-response relationship for epibatidine on the ACR-16-like
receptor from T. muris and T. suis. The efficacy, Imax, of epibatidine was higher, 25.7 ± 0.5%
(n = 11) for the Tmu-ACR-16-like receptor as compared to 11.1 ± 0.5% (n = 8) for the
Tsu-ACR-16-like receptor (p = 0.02). In addition, the concentration-response curve revealed
an epibatidine EC50 value of 1.9 ± 0.5 µM (n = 8) for the Tsu-ACR-16-like receptor that was
in the same range as the one from the Tmu-ACR-16-like receptor (1.7 ± 0.4 µM, n = 11).
The ACR-16-like and the ACR-19 both belong to the ACR-16 group of nAChR subunits;
however, only the Tmu-ACR-16-like subunits gave rise to a functional AChR. Because co-
expressions of closely related AChR subunits, such as DES-2 and DEG-3 from C. elegans [35],
as well as ACR-26 and ACR-27 from the livestock strongyle H. contortus and the horse
ascarid parasite P. equorum [27], have been described as a requirement for the reconstitution
of functional heteromeric AChRs, we hypothesized that the ACR-16-like and ACR-19 sub-
units from T. muris could assemble into a heteromeric receptor. Therefore, we microinjected
equimolar concentrations of Tmu-acr-16-like and Tmu-acr-19 cRNAs (together with Xla-ric-
3) in X. laevis oocytes. Co-expression of Tmu-acr-16-like and acr-19 produced functional
channels that responded to ACh and displayed an ACh EC50 value of 37.9 ± 0.5 µM (n = 6)
which was not significantly different from the EC50 value obtained for the homomeric
Tmu-ACR-16-like receptor (31.1± 0.3 µM, n = 16). The concentration-response relationships
of ACh (0.3 µM–1 mM) on the putative Tmu-ACR-19/Tmu-ACR-16-like- and the Tmu-ACR-
16-like receptor are shown in Figure 3d. These results could suggest that Tmu-ACR-16-like
does not assemble into functional heteromultimers with Tmu-ACR-19.
3. Discussion
In the present study, we report for the first time the identification and the expression
of a functional AChR from the model parasitic nematode T. muris. Indeed, there was to our
knowledge no functional characterization of any ion channels from T. muris reported to
date. We showed that the amino-acid sequence of the Tmu-ACR-16-like subunit is highly
conserved with the T. suis orthologue. As with the T. suis O-AChR, we found that the
Tmu-ACR-16-like subunit gave rise to a functional homomeric AChR highly sensitive to
oxantel when expressed in Xenopus oocytes. These results additionally explain the high
efficacy and specificity of oxantel on whipworm species, and suggest that T. muris is a valid
pharmacological model for T. trichiura at least in relation to oxantel.
Most importantly, we also report that the pharmacology of the ACR-16-like receptor
from the genus Trichuris is not identical, highlighting a putative different pharmacological
profile of T. muris and T. suis. These differences emphasize the importance of species-
specific drug-target characterization and caution in transferring data interpretation between
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Trichuris spp.; perhaps these differences even suggest that drug discovery programs should
be species-specific.
Here, we found that oxantel acted as a partial agonist with similar potency as ACh,
epibatidine acted as a partial agonist with a higher potency than ACh, whereas pyrantel
induced only a minor response on the Tmu-ACR-16-like receptor. These findings emphasize
species-specific differences at the receptor level, since oxantel acted as a full-, pyrantel as a
partial-, and epibatidine as a weak agonist on the Tsu-ACR-16-like receptor [30]. Oxantel
was predicted to bind to the ACR-16 of T. muris (Tmu-ACR-16-like) with high affinity
in a recent in silico ligand binding analysis of the extracellular domains of nematode
ACR-16 nAChRs [38]. Our results support these predictions, but also show that oxantel
acts as a partial agonist on the Tmu-ACR-16-like receptor. Oxantel may therefore exert
its anthelmintic effect by reducing either the potency or the efficacy of the natural ligand
ACh. Nevertheless, oxantel is more efficient than the cholinergic anthelmintics, pyrantel,
levamisole, and monepantel against T. muris in vitro [19,20,22] and has excellent trichuri-
cidal properties in mice [20]. As the potency of oxantel was similar to ACh in our study,
and presuming that the Tmu-ACR-16-like receptor is the major oxantel target in T. muris,
we therefore refer to the Tmu-ACR-16-like receptor as an O-AChR subtype similar to the
O-AChR from T. suis. To our knowledge, there are only a few studies investigating the
effect of oxantel on mammalian nAChRs. A recent in vitro receptor binding assay reports
oxantel to bind to the human α7 with an estimated maximal inhibitory concentration (IC50)
of 3.48 µM. A similar binding assay was performed using the whole brain membranes
(minus cerebellum) from Wistar rats, which contains nAChR, here an estimated IC50 value
of 33 µM was reported [42]. For comparison, the IC50 value of oxantel pamoate for the
larvae stage 4 (L4) of T. muris has previously been reported to be 3.9 µM [20], which by the
authors is categorized as in the same order as the IC50 values for the mammalian nAChRs.
It should be noted that the authors emphasize the IC50 values of the nAChRs to be inter-
preted with caution as data are insufficient [42]. The α7 subunit from chicken has been
expressed in X. laevis oocytes and assayed with oxantel [43]. An approximate EC50 value
of 80 µM oxantel was found, which is considerably higher than for the Tmu-ACR-16-like
receptor (i.e., 32.7 ± 0.3 µM).
The pamoate salt of oxantel, used in treatment of human trichuriasis, limits the ab-
sorption of oxantel, which is stated to be approximately 8–10%, allowing the anthelmintic
to reach therapeutic levels in the lower part of the intestine where Trichuris spp. are situ-
ated [14,44]. Permeability of intestinal epithelial to oxantel pamoate has been evaluated
in vitro using Caco-2 cells. The mean apical to basolateral and basolateral to apical perme-
ability was 0.2 and 0.4 × 10−6 cm/s, respectively. This was in the same range as colchicine
and was therefore by the authors considered to be low permeability [42]. The poor gastroin-
testinal drug absorption has been evaluated in vivo by Cowan et al. [45] who found the
plasma level concentrations to be below the limit of quantification after oral administration
of 100 mg/kg oxantel pamoate to mice, the poor systemic bioavailability has also been
confirmed in rats [46]. Non-detectable levels of oxantel pamoate in the plasma may be
due to metabolism of the parent compound. However, oxantel pamoate has been found
to be metabolic stable when incubating oxantel pamoate with human and rat intestinal
microsome. Due to the metabolic stability and poor absorption, hepatic metabolism has
not been further evaluated [42]. It is assumed that oxantel pamoate primarily stays in
the intestinal tract; however, further pharmacokinetic studies are suggested for Phase
I studies [42]. The clinical safety of oxantel pamoate has been evaluated in a parallel,
randomized, placebo-controlled, single-blind trial using six different dose levels between
5–30 mg/kg. In this study, the frequency of side effects seemed to be independent of the
oxantel pamoate dose [18]. According to Quantrel® (oxantel pamoate-pyrantel pamoate)
package information leaflet, side effects, if occurring, are usually related to the gastrointesti-
nal tract. This is in line with oxantel pamoate primarily stays in the gastrointestinal tract
where it is believed to interact with nAChRs located in human intestinal cells. However,
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Palmeirim et al. (2021) [42] reviewed clinical trials implemented after 2000, and reported
that the most common side effects described were stomach pain and headache.
Epibatidine is a toxic alkaloid, isolated from the skin of the Ecuadorian poison frog
Epipedobates tricolor used by indigenous tribes in darts for hunting [47]. The great interest
in epibatidine arose with the discovery of its analgesic effect mediated by non-opioid
receptors [48]. Epibatidine interacts with nAChRs in the neuro-muscular junction and the
central nervous system [49], but due to its high toxicity in mammals it is not desirable as
a future anthelmintic compound. However, it is interesting to note that the sensitivity of
the ACR-16-like receptor to epibatidine varies between Trichuris spp. emphasizing the
importance of species-specific receptor characterization. Pyrantel-induced activation has
been associated with glutamic acid in ligand binding loop B [50,51] and a glutamine in
loop D [50]. Recently it was noted by Kaji et al. [38] that all characterized ACR-16 subunits
lack these residues and instead possess an analogous loop D aspartic acid and loop B
glycine. These residues could therefore explain the lack of efficacy to pyrantel but not the
differential sensitivities to pyrantel between ACR-16 nAChRs from the zoonotic hookworm
of dogs, A. ceylanicum, and the human hookworm N. americanus. The divergent ACR-16-like
subunits of T. muris and T. suis possess only the loop B glycine (position 179 in Figure S1),
but have an analogous loop D lysine (position 82 in Figure S1). The lysine could explain
why the ACR-16-like receptor of Trichuris spp. has a different sensitivity to pyrantel, but
in line with Kaji et al., this residue cannot explain why the ACR-16-like receptor from T.
muris is less sensitive to pyrantel (mean ± SEM, 4.6 ± 0.8%) than the ACR-16-like receptor
from T. suis (26.1 ± 2.1%) [30]. Our results therefore suggest that additional residues may
be involved in pyrantel-induced activation. However, it is important to recall that pyrantel
has no effect against adult Trichuris [13], and that pyrantel preferentially targets another
AChR subtype made of the subunits UNC-29, UNC-38 and UNC-63 isolated from the pig
nodular worm Oesophagostomum dentatum [52].
The pharmacological differences between the ACR-16-like receptors of T. muris and
T. suis may be attributed to several different residues within the ligand binding loops. In
general, the ligand binding loops of the Tmu-ACR-16-like subunit diverge the most from
T. suis and T. trichiura, whereas the binding loops of T. suis and T. trichiura are highly similar,
with only one residue in loop E that differs (Met144 in T. suis instead of Val in T. muris and
T. trichiura). This valine has previously been speculated to accommodate more space to
oxantel within the binding pocket [38], but as T. suis has Met163 and oxantel acts as a full
agonist on the Tsu-ACR-16-like receptor, it is more likely that other residues in the binding
loops are of greater importance in relation to oxantel binding. However, the high identities
of the ACR-16-like subunits (i.e., 93%) from T. suis and T. trichiura, and particularly the
high similarities of the ligand binding loops suggest a comparable pharmacology of these
species, at least in relation to the ACR-16-like receptor. Future pharmacological studies
on the ACR-16-like receptor from T. trichiura would provide important information on the
amino acids involved in the sensitivity to oxantel.
The attempt to reconstitute a functional AChR using the nematode ACR-19 subunit has
so far never been described, even in the model nematode C. elegans. Here, we explored for
the first time whether the Tmu-ACR-19 subunit could form either a functional homomeric-
or a heteromeric receptor when expressed in X. laevis oocytes either alone, or in combination
with Tmu-ACR-16-like subunits. We observed no difference in ACh sensitivities between
the eggs injected with Tmu-acr-16-like alone and the eggs co-injected with Tmu-acr-16-
like/acr-19 cRNAs. We therefore proposed that the current responses were due to the
functional homomeric Tmu-ACR-16-like receptor and not a heteromeric ACR-19/ACR-16-
like receptor. However, we cannot rule out the possibility that there might be a heteromeric
ACR-19/ACR-16-like receptor with a sensitivity to ACh similar to the one of the ACR-
16-like receptor. More pharmacological and biochemical investigations will be needed to
address this hypothesis. The reason for lack of receptor functionality is presently unclear.
There is currently a lack of knowledge of which nAChR subunit(s) and/or ancillary and/or
auxiliary proteins are required to form a functional receptor including the ACR-19 subunit.
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Upstream regulation of acr-19 expression by acr-15 has been reported for C. elegans in
response to chronic nicotine exposure [53]. It is, therefore, possible that some functional
association exists between acr-15 and acr-19 in C. elegans. The ACR-15 subunit is in the
ACR-16 group of C. elegans [54]; however, we and others have found an acr-15 subunit in the
genome of Clade I parasitic nematodes [35]. It is, therefore, unlikely that ACR-15 is required
for the expression of a functional receptor including the ACR-19 subunit in Trichuris spp.
The nAChRs from numerous organisms, including C. elegans, have been shown to require
various ancillary or auxiliary proteins such as RIC-3, UNC-50 (UNCoordinated-50) and
UNC-74 (UNCoordinated-74), EAT-18 and MOLO-1 (MOdulator of LevamisOle receptor-1)
for functional expression [39,55–57]. In this study, we only used the ancillary protein
RIC-3, hence, we cannot exclude the requirement of some of the above-mentioned, or yet
unidentified, ancillary or auxiliary proteins.
4. Materials and Methods
4.1. Ethic Statement
Animal experiments were performed under the regulations of the UK Home Office
Scientific Procedures Act (1986) and were subject to local ethical review by the Univer-
sity of Manchester Animal Welfare and Ethical review Body (AWERB) and followed
ARRIVE guidelines.
4.2. Experimental Animals and Infections
The worm material used in this study was of the Edinburgh strain, originally obtained
from The Wellcome Research Laboratories, London [58], and was isolated from 6–8-week-
old male Severe Combined Immunodeficient (SCID) mice infected with 400 T. muris eggs by
oral gavage. Forty-two days later, mice were killed using CO2 and the cecum and proximal
colon were removed. The cecum and colon were split and washed in RPMI 1640 medium
plus 500 U/mL penicillin and 500 µg/mL streptomycin (Sigma-Aldrich UK). Adult worms
of both sexes were removed using fine forceps and washed using the above medium three
times before being placed in 100% ethanol.
4.3. Drugs
All drugs were purchased at Sigma-Aldrich (France). Stock solutions were made in
either recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O, 5 mM HEPES,
pH 7.3) or DMSO (100%) and stored at either −20 or 4 ◦C until use. Before use, stock
solutions were dissolved in recording buffer with a maximum final concentration of DMSO
of 0.1%.
4.4. Sequence Analysis and Alignment
The Tsu-ACR-16-like (accession number MT386096) and the Tsu-ACR-19 (accession
number KFD70086) were used as queries in database searches for amino-acid sequences of
ACR-16-like and ACR-19 from T. muris using the protein-protein BLAST (BLASTp) service
at the National Center for Biotechnology Information (NCBI) service [59]. The Tsu-ACR-
16-like and the Tsu-ACR-19 were used in an alignment with the identified sequences. The
accession numbers of the identified sequences used for the alignment are: Trichuris muris:
ACR-16-like MZ322663; ACR-19 WBGene00291941. Trichuris suis: ACR-16-like MT386096;
ACR-19 KFD70086. Trichuris trichiura: ACR-16-like CDW52185; ACR-19 CDW53523. Homo
sapiens: α7 subunit isoform 1 P36544. Signal peptide was predicted using the SignalP 4.1
server [60] and the transmembrane regions were predicted using the TMHMM version 2
server [61]. Deduced amino-acid sequences were aligned using the MUSCLE algorithm [62]
and additionally processed in GeneDoc (IUBio). The accession numbers of the ACR-16-
like and ACR-16 sequences from Clade I, III and V nematodes used for the alignment
to show the ligand binding loops in the ECDs are: Trichuris muris: MZ322663; Trichuris
suis: MT386096; Trichuris trichiura: CDW52185; Ascaris suum: KP756901; Parascaris equo-
rum: AZS27834.1; Caenorhabditis elegans: CCD64102.1; Haemonchus contortus: AZS27833.1;
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Ancylostoma ceylanicum: MT163735; Ancylostoma caninum: QEM53385; Necator americanus:
MT163736.
4.5. Cloning of the Coding Sequence of the ACR-16-Like and ACR-19 Subunits from
Trichuris muris
Total RNA was extracted from T. muris using NucleoSpin RNA XS kit and subse-
quently treated with rDNase (Macherey-Nagel, France). First strand cDNA synthesis
was performed with 0.8 µg of total RNA using the Maxima H minus Reverse Transcrip-
tase kit (Thermo Scientific, MA, USA) according to the manufacturers’ recommendations.
The full-length coding sequences of Tmu-acr-16-like and Tmu-acr-19 were obtained with
nested PCRs using the Phusion High Fidelity Polymerase (New England BioLabs, MA,
USA) and the first strand cDNA as a template. Primer sequences were designed based
on predicted coding sequences of the Tmu-acr-16-like subunit (WBGene00290200), and the
putative Tmu-acr-19 (WBGene00291941) available in Wormbase Parasite, version VBPS15
(WS276). The first round of PCRs was performed with the primer-combination F0/R0
and the second round with F1/R1 of which the latter contained the XhoI and ApaI re-
striction enzyme sites and a 11–14 bp nucleotide overhang complimentary to 11–14 bp
in the linearized expression vector pTB-207. The primer pair sequences were as fol-






The purified PCR products were cloned into the expression vector pTB-207 using the
In-Fusion HD Cloning kit (Clontech). Constructs were verified by sequencing, and the
pTB-207-Tmu-acr-16-like linearized with the restriction enzymes PaeI and NheI and the pTB-
207-Tmu-acr-19 with NehI. cRNAs synthesis were performed using mMessage mMachine
T7 transcription kit (Ambion), purified on NucleoSpin RNA columns (Machery–Nagel)
and kept at −80 ◦C until use.
4.6. Electrophysiological Experiments in Xenopus laevis Oocytes
Xenopus laevis oocytes were purchased from Ecocyte Biosciences (Castrop-Rauxel
Germany) and kept at 19 ◦C in incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM
CaCl2·2H2O, 1 mM MgCl2·6H2O, 5 mM HEPES, 2.5 mM C3H3NaO3, supplemented with
100 U/mL penicillin and 100 µg/mL streptomycin, pH 7.3). The requirement of the
chaperone protein RIC-3 for functional expression of the ACR-16-like receptor of T. suis has
previous been described ([30]), hence, we co-injected each oocyte with 5 ng cRNA of Xla-ric-
3 and 25 ng cRNA of either Tmu-acr-16-like, Tmu-acr-19, Tsu-acr-16-like, or Tmu-acr-16-like
and Tmu-acr-19 in a total volume of 37 nL using. The oocytes were incubated for 3–5 days in
incubation solution to allow for receptor expression. The function and the pharmacological
properties of the resultant receptors was explored 3–5 days after microinjection on oocytes
clamped at −80 mV using two-electrode voltage-clamp recordings obtained with the
fully automated system Robocyte2 (Multichannel systems MCS GmbH, Germany). All
experiments were performed with oocytes pre-incubated in 100 µM BAPTA-AM for 3.5 h
in order to chelate intracellular Ca2+ ions and hereby prevent activation of endogenous
calcium activated chloride channels during recordings [63]. The drug efficacy test was
performed using 3 individual oocyte batches (n = 7–10 per batch). Each oocyte was initially
exposed to 100 µM ACh for 10 s and subsequently to 100 µM of each of the 4 cholinergic
anthelmintics; oxantel, pyrantel, morantel and levamisole, and the 5 nicotinic agonists;
epibatidine, anabasine, DMPP, nicotine, and cytosine for 10 s each. Between each drug
application, a wash-out period of 2 min with recording solution was applied. For individual
eggs, peak current responses of each agonist was normalized to the peak current response
induced by 100 µM ACh. The dose-response tests with the Tmu-ACR-16-like receptor
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were performed using 2 individual oocyte batches (n = 7–11 per batch), whereas the dose-
response tests with the ACR-16-like receptor from T. suis, and the putative heteromeric Tmu-
ACR-16-like/Tmu-ACR-19 receptor were performed on a single batch of oocyte (n = 6–8).
First, the dose-response relationship of ACh was established at concentrations between
0.3 µM–1 mM. The current response, at which the maximum mean peak current to ACh
was obtained, was used to normalize all other responses of ACh (0.3 µM–1 mM), oxantel
(0.3–300 µM) and epibatidine (0.03–30 µM). Consequently, each oocyte exposed to oxantel
and epibatidine was first challenged with 300 µM ACh.
4.7. Statistical Analysis
All acquired electrophysiological data were analyzed with Clampfit 10.7 (Molecular
Devices, Sunnyvale, CA, USA) and GraphPad Prism 9 (GraphPad Software, La Jolla, CA,
USA). All data analysis was performed on normalized current values. For the efficacy
tests, the normalized drug-group means were statistically analyzed using a non-parametric
Kruskal–Wallis Test with a Dunn’s multiple comparison test, where p < 0.05 was considered
significant. The dose-response relationships were established by fitting the normalized
currents as a function of drug concentration to a Hill equation using non-linear regression
analysis with a variable slope model. The following equation was used:
Irel = Imin + (Imax − Imin)/(1 + 10ˆ((LogEC50 − [D])*nH))
where Irel is the mean relative current, Imax, is the relative current obtained at saturating
agonist concentration, Imin is the relative current obtained at agonist concentrations 0 µM,
EC50 is the concentration of agonist at which 50% of the maximal current response is
obtained, [D] is the drug concentration and nH is the Hill coefficient. Imax, EC50, and nH
were fitted as free parameters whereas Imin, was constrained to 0.
5. Conclusions
In summary, this study confirms that the ACR-16-like receptor from T. muris is a
preferential drug target for oxantel, thus an O-AChR subtype such as the ACR-16-like
receptor from T. suis. Our data therefore support previous findings, which provided new
insight for the high efficacy and specificity of oxantel on whipworms and emphasize
the potential importance of species-specific pharmacological characterization for future
anthelmintic discovery programs.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14070698/s1, Figure S1: Amino-acid alignment of the ACR-16-like subunit from T. muris
(Tmu), T. suis (Tsu) and T. trichiura (Ttr) and the ACR-16 subunits from the Clade III parasitic
nematodes A. suum (Asu), P. equorum (Peq) and the Clade V nematodes C. elegans (Cel), A. ceylanicum
(Ace), A. caninum (Aca), N. americanus (Nam) and H. contortus (Hco). Conserved amino acids for the
ACR-16-like from Trichuris spp. are highlighted with red. The extracellular domain (ECDs) ligand
binding loops A-E are highlighted in green. * (in black) indicate amino acids residues within the
binding loops of the ACR-16-like subunit from T. muris which differ from T. suis and T. trichiura. * (in
red) indicate the amino acids residue within the binding loop of the ACR-16-like subunit from T. suis
which differ from T. muris and T. trichiura. Predicted signal peptide sequences are shaded in dark
green, the transmembrane regions (TM1-TM4) are shown below the sequences.
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